Data layers Raw facts Calculated Model prediction AI interpretation

Company Overview

Stock NameHBM Holdings-B
Stock Code02142
Company Full NameTo be extracted
IndustryHealthcare
Principal Activities臨床階段生物製藥公司,從事研究及開發免疫與腫瘤疾病領域的差異化抗體療法,擁有多元化候選藥物管線及和鉑抗體平台。
Listing Date2020-12-10
Listing Rules EraOld Rules
Listing Rules Chapter18A生物科技
Weighted Voting Rights (WVR)No
Registered Address (Mainland China)中国上海市徐匯區楓林路420號楓林國際大廈二期A座12樓
Business Address (Hong Kong)香港皇后大道東183號合和中心54樓
Place of IncorporationTo be extracted
Listing MethodTo be extracted
Listing BoardMain Board
Websiteharbourbiomed.com
Share Registrar卓佳证券登记有限公司 (Tricor Investor Services Limited)
Registrar Contact(852)2980 1333
A-Share/US Dual ListingNo

Offering Information

Offering Mechanism Mechanism A
Offer PriceHK$ 12.38 / shares
Offer Price RangeFinal offer price only, no range
Lot Size1,000 shares
Entry ThresholdHK$ 12,380
Par ValueTo be extracted
Offer Period2020-11-30 to 2020-12-03
Global Offering Shares138,221,000 shares
HK Public Offer Shares (Initial)13,824,000 shares (10.0%)
Public Offer Lots (Initial)13,824lots (Pool A6,912lots,Pool B6,912lots)
International Placing Shares (Initial)124,397,000 shares (90.0%)
Offer Ratio~10.0%
Total Shares Post-IPO767,891,160 shares
Greenshoe (Over-allotment Option)Yes
Stabilizing Manager (Greenshoe)To be extracted
Cornerstone Share41.7%
Clawback TiersTo be extracted
Reallocation OptionYes
Total Global Offering SizeHK$ 1,711,175,980

Subscription Tiers

Minimum subscription unit: 1 lot. Subscription amount ≤ HK$5,000,000 is Pool A, > HK$5,000,000 is Pool B.

Pool A
Lots SubscribedShares SubscribedSubscription Amount (HKD)
1 lots 1,000 HK$ 12,380
2 lots 2,000 HK$ 24,760
3 lots 3,000 HK$ 37,140
4 lots 4,000 HK$ 49,520
5 lots 5,000 HK$ 61,900
6 lots 6,000 HK$ 74,280
7 lots 7,000 HK$ 86,660
8 lots 8,000 HK$ 99,040
9 lots 9,000 HK$ 111,420
10 lots 10,000 HK$ 123,800
15 lots 15,000 HK$ 185,700
20 lots 20,000 HK$ 247,600
25 lots 25,000 HK$ 309,500
30 lots 30,000 HK$ 371,400
35 lots 35,000 HK$ 433,300
40 lots 40,000 HK$ 495,200
45 lots 45,000 HK$ 557,100
50 lots 50,000 HK$ 619,000
60 lots 60,000 HK$ 742,800
70 lots 70,000 HK$ 866,600
80 lots 80,000 HK$ 990,400
90 lots 90,000 HK$ 1,114,200
100 lots 100,000 HK$ 1,238,000
200 lots 200,000 HK$ 2,476,000
300 lots 300,000 HK$ 3,714,000
400 lots 400,000 HK$ 4,952,000
Pool B
Lots SubscribedShares SubscribedSubscription Amount (HKD)
500 lots 500,000 HK$ 6,190,000
600 lots 600,000 HK$ 7,428,000
700 lots 700,000 HK$ 8,666,000
800 lots 800,000 HK$ 9,904,000
900 lots 900,000 HK$ 11,142,000
1,000 lots 1,000,000 HK$ 12,380,000
2,000 lots 2,000,000 HK$ 24,760,000
3,000 lots 3,000,000 HK$ 37,140,000
4,000 lots 4,000,000 HK$ 49,520,000
5,000 lots 5,000,000 HK$ 61,900,000
6,000 lots 6,000,000 HK$ 74,280,000
6,912 lots 6,912,000 HK$ 85,570,560

Stock Connect Inclusion Analysis

HK Market Cap HK$ 10.54B
Analysis Result Already included in Stock Connect (both)

Valuation & Financials

Market Cap (at Offer Price)HK$ 9,506,492,560
Pre-IPO Valuation (Last Round)Not disclosed
P/E Ratio不適用(公司處於虧損狀態)
Profit/Loss Status亏损约67.5百万美元
Period-End Cash Balance33.4百万美元
Listing ExpensesTo be extracted
Listing Expenses / Funds RaisedTo be extracted
Total Pre-IPO Investment超過300百萬美元

Financial Data

Unit: '000 USD
Income Statement
Item 20182019
Revenue 1,4839,070
Cost of sales -905-957
Gross profit 9169,113
Other income and gains, net 926953
Administrative expenses -7,316-8,037
Net finance costs -902-972
Profit before tax -7,626-9,226
Income tax expense -715-721
Profit for the year -7,246-7,276
Profit attributable to owners -7,226-7,126
Income Statement
Source: Accountants' Report and Audited Consolidated Financial Statements
First Day CloseHK$ 11.02
First Day OpenHK$ 11.94
First Day Change-10.99%
First Day Volume57898000.0
First Day Turnover695749000.0
Use of Proceeds
1、約591.5百萬港元(占37%)預期將用于撥資我們的核心產品; 2、約367.7百萬港元(占23%)預期將用于撥資我們的支柱資產HBM4003在大中華區及澳洲的進行中及計劃進行的臨床試驗、籌備在大中華區、美國及其他司法權區的注冊備案及潛在商業化推出; 3、約239.8百萬港元(占15%)預期將用于撥資我們其他正在尋求IND批準及尚未開始臨床試驗或臨床前研究的候選藥物的研發; 4、約191.9百萬港元(占12%)預期將用于撥資和鉑抗體平臺產生的創新型分子發現; 5、約79.9百萬港元(占5%)預期將用于撥資持續改進平臺技術、利用和鉑抗體平臺尋求授權及合作機會; 6、約127.9百萬港元(占8%)預期將用作營運資金及其他一般企業用途。

Underwriting Syndicate

Joint Sponsors (3)
Morgan Stanley Asia Limited CE AAD291 Merrill Lynch (Asia Pacific) Limited CE AAC198 中信证券(香港)有限公司 CE AAK249
Overall Coordinators (5)
Morgan Stanley Asia Limited CE AAD291 Merrill Lynch (Asia Pacific) Limited CE AAC198 CLSA LIMITED CE AAB893 中国国际金融香港证券有限公司 CE AEN894 Credit Suisse (Hong Kong) Limited CE AAO017
Joint Bookrunners (7)
Morgan Stanley Asia Limited CE AAD291 Merrill Lynch (Asia Pacific) Limited CE AAC198 CLSA LIMITED CE AAB893 中国国际金融香港证券有限公司 CE AEN894 Credit Suisse (Hong Kong) Limited CE AAO017 海通国际证券有限公司 CE AAF806 中银国际亚洲有限公司 CE AET863
Joint Lead Managers (5)
Morgan Stanley Asia Limited CE AAD291 Merrill Lynch (Asia Pacific) Limited CE AAC198 CLSA LIMITED CE AAB893 中国国际金融香港证券有限公司 CE AEN894 Credit Suisse (Hong Kong) Limited CE AAO017

Cornerstone Investors

#Investor NameInvestment AmountShares Subscribed% of Offer Shares% of Total SharesLock-up PeriodEst. Unlock Date
1 3W Funds 38,761,780 HKD — 2.27% — 6 months 2021-06-10
2 Anlan Funds 54,261,540 HKD — 3.17% — 6 months 2021-06-10
3 BlackRock Funds 232,595,440 HKD — 13.59% — 6 months 2021-06-10
4 HBM Healthcare Investments (Cayman) Ltd. 77,523,560 HKD — 4.53% — 6 months 2021-06-10
5 Hillhouse Funds 77,523,560 HKD — 4.53% — 6 months 2021-06-10
6 Hudson Bay Master Fund LTD 77,523,560 HKD — 4.53% — 6 months 2021-06-10
7 LC HEALTHCARE FUND I, L.P. 38,761,780 HKD — 2.27% — 6 months 2021-06-10
8 Octagon Investments Master Fund LP 77,523,560 HKD — 4.53% — 6 months 2021-06-10
9 OrbiMed Funds 38,761,780 HKD — 2.27% — 6 months 2021-06-10

Directors & Management

PositionChinese nameEnglish Name
Chairman王勁松—
Company Secretary呂穎一—
No director data available.

Major Shareholders

Major Shareholders & Holdings永豐利投資有限公司持股12.18%,LC Healthcare Fund I, L.P.持股8.53%,HARBOURBIO LLC持股7.86%,王勁松持股7.86%,Owap Investment Pte Ltd.持股6.59%
About this page

This page shows HBM Holdings-B (02142) prospectus details: offer price range, fundraise size, cornerstone investors, greenshoe, Pool A/B allocation and syndicate. For eligible IPOs it also provides a Stock Connect inclusion analysis, indicating the pathway and estimated timing for Southbound Connect admission; for A-share / US secondary listings, it additionally compares the other market's price, exchange rate and the H-share premium/discount. Data is parsed from the HKEX prospectus and related announcements. New to IPO subscription? See Hong Kong IPO Subscription 101.

Cibo — HK IPO Allotment Forecasts, Allottee Profiling & Stock Connect